ERBB2 and breast cancer: Strikingly, in a clinically relevant HER2pos BC model, HER2-DC1 i.t. combined with anti-HER2 antibodies treatment showed a superior antitumor response compared with standard chemotherapy combined with anti-HER2 antibodies.